Market Overview

H.C Wainwright Initiates X T L Biopharmaceuticals With Buy

48 Biggest Movers From Yesterday
38 Stocks Moving In Tuesday's Mid-Day Session

Analysts at H.C Wainwright initiated coverage on X T L Biopharmaceuticals Ltd (ADR) (NASDAQ: XTLB) with a Buy rating.

The target price for XTL Biopharmaceuticals is set to $6.

XTL Biopharmaceuticals shares have dropped 30.58 percent over the past 52 weeks, while the S&P 500 index has surged 11.15 percent in the same period.

XTL Biopharmaceuticals' shares rose 14.14 percent to $2.30 in pre-market trading.

Latest Ratings for XTLB

May 2015H.C. WainwrightInitiates Coverage onBuy

View More Analyst Ratings for XTLB
View the Latest Analyst Ratings

Posted-In: H.C WainwrightInitiation Analyst Ratings


Related Articles (XTLB)

View Comments and Join the Discussion!

Raymond James Initiates Fulton Financial With Market Perform

Benzinga's Top Upgrades